One study suggests that breast cancer cells with FGFR1 alterations that exhibit resistance to CDK4/6 inhibitors and fulvestrant can be overcome by combining the FGFR tyrosine kinase inhibitor (TKI) with CDK4/6 inhibitors and ER antagonists [34]. The gene discussed is CDK4; the disease is breast cancer.